Nautilus gets funding to support migraine drug launch

New Jersey's Nautilus Neurosciences has received an undisclosed investment from Galen Partners to support commercialization of its migraine treatment Cambia, which is set to launch in the first half of this year. The company was founded in November 2009 and with the help of funding from Tailwind Capital. Nautilus also has a second drug candidate--PRO-571 for acute pain--in clinical trials. "Over the past six months we have raised approximately $25 million," says James...